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Is there a hypercoagulable state after off-pump coronary
artery bypass surgery? What do we know and what can
we do?
Paul A. Kurlansky, MD
Coronary artery bypass graft (CABG) surgery on a beating heart wasintroduced with suture techniques and local stabilization by Ko-lessov in 1967.1 However, cardiopulmonary bypass and cardiople-gic arrest, with their ability to provide a quiet bloodless field for theconstruction of precise and delicate surgical anastomoses, offeredcompelling advantages compared with the off-pump approach and
rapidly became more widely accepted.2 With the dramatic reduction of operative
mortality throughout the ensuing decades, surgeons began to focus their attention on
decreasing operative morbidity, especially conditions associated with neurologic
and systemic inflammatory influences after CABG surgery. Traditionally, many of
these sequelae have been ascribed to the use of cardiopulmonary bypass.
During the past decade, there has been a dramatic resurgence in the application
of off-pump technology in CABG surgery. This has inspired remarkable advances
in the techniques of localized tissue stabilization and a greater understanding of the
physiology of beating heart mobilization and exposure. An avalanche of reports in
the literature has demonstrated the early safety and efficacy of the procedure.3 More
than 20% of CABG procedures performed nationwide apply off-pump technology.
However, considerable controversy remains regarding the relative merits and long-
term outcomes of this approach to coronary revascularization.4
One area of concern, and even greater uncertainty, surrounds the issue of the
existence of a hypercoagulable state after off-pump CABG surgery. Are patients
undergoing off-pump CABG surgery relatively more hypercoagulable postopera-
tively than their counterparts undergoing on-pump CABG surgery? Such a hypoth-
esis is indeed reasonable in view of the acute phase activation of clotting factors that
follow off-pump CABG surgery (as well as surgery in general) and the lack of
platelet, fibrinolytic, and other abnormalities related to the heart-lung machine.
However, there was no evidence to indicate a clinical problem associated with the
procedure until Mariani and colleagues5 awakened our concern with their report in
1999. They reviewed 22 consecutive off-pump cases and found a postoperative
increase in procoagulant activity, represented by prothrombin factor 1 and 2, which
was also accompanied by an increase in von Willebrand factor (endothelial activa-
tion) and fibrinolysis. Although Mariani and colleagues5 demonstrated no clinical
sequelae during their brief follow-up of this limited series of patients with internal
thoracic artery (ITA) grafts, they recommended the institution of an aggressive
perioperative anticoagulant regimen in all off-pump CABG cases.
What is the major concern? Clearly, a pattern of deep venous thrombosis,
pulmonary embolism, or arterial thrombosis would be a source of serious concern
to the cardiac surgeon. However, the already extensive clinical experience fails to
demonstrate such a pattern. Perhaps a less apparent concern would be the occurrence
of acute graft closure. Careful evaluation of the current body of knowledge would
indicate just the opposite, with acute graft patency rates exceeding 90% in virtually
all cases reviewed. The information in Table 1 summarizes the results of a series of
angiographic patency studies after off-pump CABG surgery.6-15 Even accounting
for extensive variability in patient selection, operative technique, and heparin and
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antiplatelet regimens in these studies, it does not seem that
acute graft closure secondary to a hypercoagulable state is a
valid clinical concern.
Careful analysis of the data exposes a more menacing
problem. Kim and associates14 conducted a 3-group study
that compared a cohort of patients undergoing off-pump
CABG surgery, a group of patients undergoing on-pump
CABG surgery, and a similar group of patients undergoing
on-pump CABG surgery whose grafts were constructed on
the beating heart during the pre-off–pump CABG learning
phase. At 1-year follow-up, ITA patency was similar among
the groups. Saphenous vein graft (SVG) patency was 88%
in patients undergoing CABG surgery, 87% in patients
undergoing on-pump beating heart surgery, and 68% in
patients undergoing off-pump surgery (P  .01).14 There
are many questions that can be raised about a retrospective
study of nonconcurrent groups of patients who underwent
operations at different points during the learning curve and
with variable follow-up. The major underlying issue is more
subtle and one that must be addressed.
It has been learned from multiple pathologic and clinical
studies that vein graft disease takes many forms: thrombosis
(acute), intimal hyperplasia (subacute), and graft atheroscle-
rosis (chronic).16 Although intimal hyperplasia may take
months to occur, and atherosclerosis 1 year or more to
develop, the initiating events (intimal injury, platelet acti-
vation, thrombus formation, macrophage infiltration, and
smooth muscle cell activation) all occur in the acute post-
operative period of SVG (but not during ITA) healing.
Therefore, during the early postoperative period, even in the
TABLE 1. Angiographic patency after off-pump coronary bypass surgery
Author Year Operation Patients Angio timing Conduit Patency
Mack and colleagues6 1999 MIDCAB 100/103 (97) 96 h LITA 99/100 (99) A*
91/100 (91)
Izzat and colleagues7 1999 OPCAB 24/24 (100) Intraoperative LITA 22/24 (92) Before
revision
SVG 18/18 (100)
Diegler and colleagues8 1999 MIDCAB 221/271 (82) 2-6 postoperative days LITA 218/221 (99)
195/221 (89) A*
23/221 (10) B*
3/221 (1) C*
Akpinar and colleagues9 2000 OPCAB 71/126 (56) Before discharge LITA 71/71 (100)
All types 143/150 (95)
Omeroglu and colleagues10 2000 OPCAB 70/696 (10) 24-61 mo LITA 65/68 (96)
RITA 1/1 (100)
Random SVG 82/103 (80)
Zehr and colleagues11 2000 OPCAB 50/50 (100) 48 h LITA 46/51 (90)
RA 15/17 (88)
SVG 73/76 (96)
Amano and colleagues12 2001 MIDCAB/OPCAB 80/194 (41) Before discharge All types 201/203 (99)
Bull and colleagues13 2001 OPCAB 40/40 (100) 48 h All types 105/108 (97)
Kim and colleagues14 2001 OPCAB 112/122 (92) 96 h ITA 139/145 (96)
130/145 (90)
RA 13/13 (100)
RGEA 10/10 (100)
SVG 157/187 (84) A*
90/122 1 y ITA 114/117 (97) A*
101/117 (86)
RA 8/8 (100)
RGEA 7/7 (100)
SVG 106/156 (68)
92/156 (59) A*
Puskas and colleagues15 2001 OPCAB 167/200 Before discharge LITA 158/158 (100)
143/158 (91) A*
RITA 4/4 (100)
RA 24/24 (100)
22/24 (92) A*
SVG 208/213 (98)
203/213 (95) A*
Numbers in parentheses are percentages. MIDCAB, Minimally invasive direct coronary artery bypass; OPCAB, off-pump coronary artery bypass; LITA, left
internal thoracic artery; RITA, right internal thoracic artery; RA, radial artery; RGEA, right gastroepiploic artery; SVG, saphenous vein graft; A,* B,* C,*
Fitzgibbon classification.
Editorials Kurlansky
8 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
ED
ITO
RIA
L
absence of any clinically manifest adverse events, the
groundwork may be laid for the occurrence of multiple late
events, thus adversely impairing long-term graft patency. In
short, have we, in our enthusiasm to reduce perioperative
morbidity, created a sleeping giant of late graft closure?
Casati and colleagues17 compared multiple hematologic
variables in patients undergoing off-pump versus on-pump
CABG surgery. They documented that a decrease in platelet
count and activation of fibrinolysis were more profound in
on-pump surgery, whereas the activation of fibrinogen and
other acute phase reactants (consistent with the deposition
of thrombus at surgical sites of injury) seemed to be more
evident during the first postoperative day in patients under-
going off-pump CABG surgery. Therefore, patients under-
going off-pump coronary artery bypass surgery might well
be expected to be more prone to graft closure. As discon-
certing as these findings may seem, a comparative analysis
of perioperative hemostatic function in patients who did and
did not experience SVG occlusion within 3 months of
surgery found an increase in plasma plasminogen activator
inhibitor-1 activity to be the only postoperative hemostatic
measurement predictive of subsequent SVG closure.18 No-
tably, the classic atherosclerotic risk factors were found to
be more powerful predictors than the hemostatic factors, a
finding corroborated by the Cleveland Clinic experience.19
The emergence of long-term comparative studies dem-
onstrating the clinical equivalence of on-pump and off-
pump CABG surgery has been most encouraging.20 How-
ever, in the absence of convincing data, there is currently
extreme variability in the management of anticoagulation
and antiplatelet agents in off-pump CABG surgery.21
In the presence of a well-founded concern for the impact
of a relatively hypercoagulable state after off-pump CABG
surgery on long-term graft patency, and in the absence of
valid data indicating appropriate guidelines, what reason-
able recommendations can be offered at this time? First,
arterial conduits, especially in situ ITA grafts, have been
demonstrated to be less prone to the pathogenesis of late
graft closure than SVG grafts and are considered to be the
conduit of choice in myocardial revascularization. As a
result, off-pump CABG surgery may prove to be an even
stronger indication for the use of arterial grafting than
conventional on-pump surgery.
Second, risk factor modification is known to affect the
course of both graft and native coronary disease in all
patients undergoing CABG surgery, and patients undergo-
ing off-pump CABG surgery are no exception. Therefore,
careful attention to risk factor modification may prove crit-
ical in maintaining graft patency and improving long-term
clinical results.
Third, in view of the lower incidence of bleeding com-
plications after off-pump CABG surgery, consideration
should be given to limiting the reversal of heparin intraop-
eratively.22
Fourth, in view of the well-documented and common
unresponsiveness to aspirin,23 as well as the considerable
effectiveness of thienopyridines (ticlopidine and its safer
successor clopidogrel) reported in both the cardiology24and
cardiac surgical literature,25 serious consideration should be
given to the perioperative (and perhaps the prolonged post-
operative) use of clopidogrel.
Fifth, the recent success of drug-eluting stents26 raises
serious concerns regarding the use of SVGs in stentable
vessels. These data, although still early, pose a theoretical
issue in the use of combined procedures for patients unable
to receive all-arterial conduits.
Sixth, gene therapy may have a dramatic impact on
arresting the progression of SVG disease,27 and advances in
this area may have particular relevance to patients under-
going off-pump coronary artery bypass surgery.
Perhaps the most helpful recommendation would be to
direct research efforts toward managing the perioperative
hypercoagulable state and its long-term impact on graft
patency in patients undergoing off-pump coronary revascu-
larization.
References
1. Kolessov VI. Mammary artery-coronary artery anastomosis as a
method of treatment for angina pectoris. J Thorac Cardiovasc Surg.
1967;54:535-44.
2. Favaloro RG, Effler DB, Groves LK, Shelton WC, Sones FM Jr. Direct
myocardial revascularization by saphenous vein graft. Present opera-
tive techniques and indications. Ann Thorac Surg. 1970;10:97-111.
3. Hart JC, Puskas JD, Sabik JF 3rd. Off-pump coronary revasculariza-
tion: current state of the art. Semin Thorac Cardiovasc Surg. 2002;14:
70-81.
4. Gardner TJ. Off-pump CABG safer for the brain. Presented at 81st
Annual Meeting of The American Association for Thoracic Surgery,
May 9, 2001, San Diego, California.
5. Mariani AM, Gu J, Boonstra PW, et al. Procoagulant activity after
off-pump coronary operation: is the current anticoagulation adequate?
Ann Thorac Surg. 1999;67:1370-5.
6. Mack JM, Magovern JA, Acuff TA, et al. Results of graft patency by
immediate angiography in minimally invasive coronary artery surgery.
Ann Thorac Surg. 1999;68:383-90.
7. Izzat MB, Khaw KS, Atassi W, Yim AP, Wan S, El-Zufari MH.
Routine intraoperative angiography improves the early patency of
coronary grafts performed on the beating heart. Chest. 1999;115:987-
90.
8. Diegeler A, Matin M, Kayser S, et al. Angiographic results after
minimally invasive bypass grafting using the minimally invasive direct
coronary bypass grafting (MIDCAB) approach. Eur J Cardiothorac
Surg. 1999;15:680-4.
9. Akpinar B, Guden M, Sagbas E, Sanisoglu I, Aytekin V, Bayindir O.
Off-pump coronary artery bypass grafting with use of the octopus 2
stabilization system. Heart Surg Forum. 2000;3:282-6.
10. Omeroglu SN, Kirali K, Guler M, et al. Midterm angiographic assess-
ment of coronary artery bypass grafting without cardiopulmonary
bypass. Ann Thorac Surg. 2000;70:844-50.
11. Zehr KJ, Handa N, Bonilla LF, Abel MD, Holmes DR Jr. Pitfalls and
results of immediate angiography after off-pump coronary artery by-
pass grafting. Heart Surg Forum. 2000;3:293-9.
12. Amano A, Hirose H, Takahashi A, Nagano N. Off-pump coronary
Kurlansky Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 9
ED
IT
O
RI
A
L
artery bypass. Mid-term results. Jpn J Thorac Cardiovasc Surg. 2001;
49:67-78.
13. Bull DA, Neumayer LA, Stringham JC, et al. Coronary artery bypass
grafting with cardiopulmonary bypass versus off-pump cardiopulmo-
nary bypass grafting: does eliminating the pump reduce morbidity and
cost? Ann Thorac Surg. 2001;71:170-5.
14. Kim KB, Lim C, Lee C, et al. Off-pump coronary artery bypass may
decrease the patency of saphenous vein grafts. Ann Thorac Surg.
2001;72:S1033-7.
15. Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, an-
giographic patency, and resource utilization in 200 consecutive off-
pump coronary bypass patients. Ann Thorac Surg. 2001;71:1477-84.
16. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease:
pathogenesis, predisposition and prevention. Circulation. 1998;97:
916-31.
17. Casati V, Gerli C, Franco A, et al. Activation of coagulation and
fibrinolysis during coronary surgery: on-pump versus off-pump tech-
niques. Anesthesiology. 2001;95:1103-9.
18. Moor E, Blombac M, Silveira A, et al. Haemostatic function in patients
undergoing coronary artery bypass grafting: perioperative perturba-
tions and relations to saphenous vein graft closure. Thromb Res.
2000;98:39-49.
19. Lytle BW, Loop FD, Cosgrove DM, et al. Long-term (5 to 12 years)
serial studies of internal mammary artery and saphenous vein coronary
bypass grafts. J Thorac Cardiovasc Surg. 1985;89:248-58.
20. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm
outcome after off-pump and on-pump surgery in beating heart against
cardioplegic arrest studies (BHACAS 1 and 2): a pooled analysis of
two randomized controlled trials. Lancet. 2002;359:1194-9.
21. D’Ancona G, Donias HW, Karamanoukian RL, et al. OPCAB therapy
survey: off-pump clopidogrel, aspirin or both therapy survey. Heart
Surg Forum. 2001;4:354-8.
22. Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL.
Blood product use in cardiac revascularization: comparison of on-and
off-pump techniques. Ann Thorac Surg. 1999;68:1640-3.
23. Steinhubl SR. Antiplatelet agents in cardiology: the choice of therapy.
Ann Thorac Surg. 2000;70:S3-8.
24. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison
of antiplatelet and anticoagulant therapy after the placement of coro-
nary-artery stents. N Engl J Med. 1996;334:1084-9.
25. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ.
Superiority of clopidogrel versus aspirin in patients with prior cardiac
surgery. Circulation. 2001;103:363-8.
26. Teirstein PS. Living the dream of no restenosis. Circulation. 2001;
104:1996-8.
27. Mangi AA, Dzau VJ. Gene therapy for human bypass grafts. Ann Med.
2001;33:153-5.
Editorials Kurlansky
10 The Journal of Thoracic and Cardiovascular Surgery ● July 2003
ED
ITO
RIA
L
